{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-030189","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.083030+00:00","generated_at":"2026-06-18T07:09:08.184587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Quoin Pharma reports FY2022 net loss of $9.4M; advances QRX003 trials for Netherton Syndrome","bullets":["FY2022 net loss $9.4M; Q4 net loss $2.0M; cash & marketable securities $12.9M at year-end.","Dosed first patient in double-blinded placebo-controlled study of QRX003 for Netherton Syndrome.","Initiated second clinical trial of QRX003 in Netherton patients on off-label systemic therapy (FDA cleared).","Completed public offering post-quarter with ~$6M net proceeds, extending cash runway into H2 2024.","Working toward clinical testing in Australia for Scleroderma/Netherton programs in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-030189","json":"https://secwatch.observer/filing/0001104659-23-030189.json","markdown":"https://secwatch.observer/filing/0001104659-23-030189.md","text":"https://secwatch.observer/filing/0001104659-23-030189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/0001104659-23-030189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/tm238968d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:09:08.184587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f15f91dff2f940ab0e12ba2ab21225bce838c45f","claim":"Quoin Pharmaceuticals, Ltd. reported fourth quarter and full year of 2022 results: net income Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31.","evidence_excerpt":"Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31, 2022 was approximately $9.4 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671502/000110465923030189/0001104659-23-030189-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year of 2022"},{"label":"Net income","value":"Net loss for the quarter ended December 31, 2022 was approximately $2.0 million. Net loss for the year ended December 31"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}